Research


Innovation and Pharmaceutical R&D

Working Papers

Abstract: Collaboration can accelerate a patent's commercialization, or quietly bury a future rival. We model and estimate incumbents’ collaboration decisions, separating development benefits from suppressive intent, and build a support-intent index that predicts whether a deal will launch or kill an innovation. Counterfactuals highlight a trade-off: limiting suppressive deals raises success probabilities on average but can reduce investment incentives, potentially deterring high-value breakthroughs.


Work in progress